Oxford Biotherapeutics

Develop antibody drug conjugates (ADCs) to treat cancer

placeAbingdon, England, United Kingdom calendar_todayFounded 2004 groups21 employees language oxfordbiotherapeutics.com

Registered entities

Innovation

37 patent families (22 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace slowing. Cited 6,739 times.

YearFilings
201513
201613
201713
20188
20198
20205
20219
20224
20236
20243
20253
20261

Investor mix

57 investors on record.

Investor typeCountShare
Venture capital916%
Private equity35%
Bank & private debt12%
Other / undisclosed4477%
Coming soon